Keith T. Flaherty
Impact in
- Oncology top 0.01%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
Papers in
-
- Melanoma and MAPK Pathways 261
- PI3K/AKT/mTOR signaling in cancer 37
- Oncology 235
- CAR-T cell therapy research 62
- Cancer Immunotherapy and Biomarkers 55
- Cutaneous Melanoma Detection and Management 55
- Colorectal Cancer Treatments and Studies 42
- Co-authors
- Antoni Ribas (54 shared papers)Peter J. O’Dwyer (64 shared papers)Ryan J. Sullivan (80 shared papers)Grant A. McArthur (35 shared papers)Georgina V. Long (59 shared papers)David E. Fisher (21 shared papers)Paul B. Chapman (21 shared papers)Jennifer A. Wargo (37 shared papers)
- Journals
- Journal of Clinical Oncology (164 papers)Clinical Cancer Research (44 papers)Cancer Research (26 papers)Annals of Oncology (20 papers)European Journal of Cancer (19 papers)
- Partner nations
- United StatesAustraliaGermany
In The Last Decade
Keith T. Flaherty
499 papers receiving 39.6k citations
Keith T. Flaherty's Hit Papers
Peers
Comparison fields: 5 of 161
- Oncology 21.0k
- Cancer Research 4.7k
- Molecular Biology 20.6k
- Immunology 6.0k
- Pulmonary and Respiratory Medicine 5.2k
Countries citing papers authored by Keith T. Flaherty
This map shows the geographic impact of Keith T. Flaherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith T. Flaherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith T. Flaherty more than expected).
Fields of papers citing papers by Keith T. Flaherty
This network shows the impact of papers produced by Keith T. Flaherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith T. Flaherty. The network helps show where Keith T. Flaherty may publish in the future.
Co-authors
The 25 scholars most cited alongside Keith T. Flaherty, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 519 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Final Version of 2009 AJCC Melanoma Staging and Classification Hit paper breakdown → | 2009 | 3363 |
| 2 | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Hit paper breakdown → | 2010 | 2620 |
| 3 | Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual Hit paper breakdown → | 2017 | 1463 |
| 4 | Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Hit paper breakdown → | 2012 | 1390 |
| 5 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1071 |
| 6 | Mechanisms of resistance to immune checkpoint inhibitors Hit paper breakdown → | 2018 | 1035 |
| 7 | Targeted agents and immunotherapies: optimizing outcomes in melanoma Hit paper breakdown → | 2017 | 884 |
| 8 | Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 794 |
| 9 | EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib Hit paper breakdown → | 2012 | 774 |
| 10 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2018 | 690 |
| 11 | Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function Hit paper breakdown → | 2010 | 578 |
| 12 | Phase II Trial of Sorafenib in Advanced Thyroid Cancer Hit paper breakdown → | 2008 | 535 |
| 13 | Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial Hit paper breakdown → | 2017 | 490 |
| 14 | 2006 | 485 | |
| 15 | Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma Hit paper breakdown → | 2018 | 465 |
| 16 | 2012 | 431 | |
| 17 | 2007 | 420 | |
| 18 | 2015 | 409 | |
| 19 | Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2018 | 400 |
| 20 | 2008 | 396 |
About Keith T. Flaherty
Keith T. Flaherty is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Organic Chemistry, having authored 519 papers that have together received 40.2k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (261 papers), CAR-T cell therapy research (62 papers), Cancer Immunotherapy and Biomarkers (55 papers), Cutaneous Melanoma Detection and Management (55 papers), Cancer Genomics and Diagnostics (54 papers), Colorectal Cancer Treatments and Studies (42 papers), Computational Drug Discovery Methods (38 papers) and PI3K/AKT/mTOR signaling in cancer (37 papers). The work is most often cited by research in Oncology (21.0k citations), Cancer Research (4.7k citations), Molecular Biology (20.6k citations), Immunology (6.0k citations) and Pulmonary and Respiratory Medicine (5.2k citations). Keith T. Flaherty has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Antoni Ribas, Peter J. O’Dwyer, Ryan J. Sullivan, Grant A. McArthur, Georgina V. Long, David E. Fisher, Paul B. Chapman, Jennifer A. Wargo, Russell W. Jenkins and David A. Barbie. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Research, Annals of Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.